Ellis Ethan R, Josephson Mark E
Harvard Medical School, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA, 02215, USA,
Curr Heart Fail Rep. 2013 Dec;10(4):296-306. doi: 10.1007/s11897-013-0150-z.
Congestive heart failure is a major health care concern affecting almost six million Americans and an estimated 23 million people worldwide, and its prevalence is increasing with time. Long-standing tachycardia is a well-recognized cause of heart failure and left ventricular dysfunction and has led to the nomenclature, tachycardia-induced cardiomyopathy. Tachycardia-induced cardiomyopathy is generally a reversible cardiomyopathy with effective treatment of the causative arrhythmia, either with medications, surgery, or catheter ablation. Tachycardia-induced cardiomyopathy remains poorly understood and is likely under-diagnosed. A better understanding of tachycardia-induced cardiomyopathy and improved recognition of its presence in clinical practice is vital to the health of patients with this disorder. The goal of this review is to discuss the pathogenesis and clinical manifestations of tachycardia-induced cardiomyopathy, as well as approaches to its diagnosis and treatment.
充血性心力衰竭是一个重大的医疗保健问题，影响着近600万美国人以及全球约2300万人，并且其患病率正随着时间的推移而增加。长期心动过速是心力衰竭和左心室功能障碍的一个公认病因，并由此产生了“心动过速性心肌病”这一术语。心动过速性心肌病通常是一种可逆性心肌病，通过药物、手术或导管消融对致病心律失常进行有效治疗后可恢复。人们对心动过速性心肌病的了解仍然很少，而且可能存在诊断不足的情况。更好地了解心动过速性心肌病并在临床实践中提高对其的识别能力对患有这种疾病的患者的健康至关重要。本综述的目的是讨论心动过速性心肌病的发病机制、临床表现以及其诊断和治疗方法。
